Joshua Meeks

BCG has been used as an immunotherapy for bladder cancer for over 50 years, yet its immunoregulatory mechanisms and causes of resistance remain unclear. doi.org/10.1172/JCI200… Here, Joshua James Meeks @JoshMeeks, Weiguo Cui @Cui_Lab & team @NUFeinbergMed analyzed the tumor microenvironment in patients with bladder cancer, identifying dynamic regulation of myeloid-T cell interactions as a critical for outcomes of BCG. The figure shows the study design and patient cohort for immune profiling of the bladder cancer tumor microenvironment during BCG therapy. #BladderCancer #BCGtherapy

@JoshMeeks @Cui_Lab @NUFeinbergMed Divergent macrophage-regulated T cell states determine response to Bacillus Calmette-Guérin vaccine in high-risk bladder cancer: doi.org/10.1172/JCI200…

Exciting opportunity! The AUA is seeking a highly-qualified member to fill the position of AUA’s next Editor of The Journal of Urology®. 🚨 Apply by June 29, 2026 for consideration! Learn more here ➡️ bit.ly/4aQjJfH #TheVoiceofUrology

Thanks so much @MarkTysonMD & @JoshMeeks !! Very appreciative of both of your support and help with the GAIN trial A032303 @ALLIANCE_org @SWOG @eaonc @NRGonc @theNCI

Presented at #ASCO26: In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results: nej.md/3RuNe00 Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer nej.md/4dLeiiW @ASCO

We ran a mock ODAC for sasanlimab and durvalumab in high risk NMIBC. Results showed one of the agents received more support than the other. This felt surprising and is timely in vote of the recent FDA decisions. #ASCO26 👉 open.spotify.com/episode/2jMh7a…

#FDA approves a treatment for high-risk non-muscle invasive bladder cancer. fda.gov/drugs/resource…

@OncBrothers @US_FDA @BijoyTelivala @apolo_andrea @TiansterZhang @PGrivasMDPhD @RenoHemonc @dr_yakupergun @siadaneshmand @shilpaonc @DrYukselUrun It’s a big tent

Durvalumab now @US_FDA ✅ for Non-Muscle Invasive Bladder cancer based off #POTOMAC: PhIII, BCG + Durvalumab vs. BCG alone in BCG naive HR-NMIBC: - DFS waiting maturity (HR: 0.68) - 3yr mDFS 82% vs 77% - MedOncs will now see HR-NMIBC #gusm #OncTwitter

@UroDocAsh Congratulations- incredibly well deserved.

Deeply honored to receive The Tagore Medal from the Urological Society of India (USI) “The Tagore Medal is a prestigious lifetime achievement award in Uro-Oncology, presented to recognize pioneering national and global contributions, groundbreaking advances, and leadership in the field. Presented under the aegis of the USI Uro Onco Section, the award reflects a shared commitment to advancing research, education, innovation, and patient care across prostate, kidney, and bladder cancers.” Truly humbled by this recognition. @usioffice @UTMDAnderson #OncSurgery

@FaltasLab @BladderCancerUS @BCAN_Research @WeillCornell @Cornell @WCMGUcancer @WCMDeptofMed @WCMEnglanderIPM Happy birthday and congrats on the success !!

Today, on my birthday, I am overwhelmed with gratitude for my family, friends, colleagues and the privilege of doing science and caring for patients. One of the best gifts I received today was seeing the fruits of mentorship: not one, but TWO members of the Faltas Lab, Rahul Singh PhD. and Jaekwon Kim MD, PhD, received $100K Young Investigator Awards. Congratulations, Rahul and Jaekwon, on your hard work, persistence, and success. Proud and grateful to be part of your journey! It took us a few tries to spell out YIA, but we managed in the end :) #TeamScience #Mentorship

@VigneshPackiam We need @RutgersCancer to open and enroll! 🤞@SWOG

Cool trial. To me these are 2 quite different regimens. Traditional Gem/Doce therapy which our data shows capitalizes on optimized drug penetration. And a dual alternating regimen - immune activation plus an element of chemo field sterilization in between. I wonder what implications it has for further line therapy but if very high CR then it matters less Love the exploration of new combination ideas so we can more rationally optimize!

@ChapinMD @UroCancer @UroOnc @UTMDAnderson @KKBree @nnavai @jdhdavis @DrByronLee @BCottaMD @OLWMD @UroDocAsh @JustinRGregg @lislycherymd @sgswisher @ppisters Congrats @KKBree !

After 10 years as @UroOnc PD at @UTMDAnderson, Happy to announce @KKBree will assume the role As APD, she has shown an unique ability 2 connect w/fellows while maintaining the rigor needed to train today’s Uro Oncs Proud of her leadership + excited for the future #oncsurgery

@IBCG_BladderCA TMT debate on radiation toxicity #AUA26

GI-Coffee study. Coffee vs alvimopan for MIBC after cystectomy for bowel recovery. Great study. Worry about contamination of baseline coffee use across both arms.

Please open and enroll to GAIN. @eugene_pietzak gem-bcg. Bcg exposed. Great trial. We have open and enrolling @NM_Urology

@MaxKates NDV01. Gel- gem-doce Vs obs for IR. Hard to know if obs is the best control.

MR3🌑 ErdaiDRS. BCG unresponsive. (It’s like SR5-> FGFR3)

MR2🌑 FGFR3 agnostic. Ablative (noTURBT) for IR. results coming.

TIP#5 Tyra-300 IR NMIBC. oral FGFR3